13 results
Primary Objective:To compare the fate of the struts in front of the side-branch and intimal bridge formation using optical coherence tomography after treatment with the bioresorbable everolimus eluting vascular scaffold of coronary bifurcation…
Primary Objective: To compare the fate of the struts in front of the side-branch and intimal bridge formation after treatment with optical coherence tomography between the bioresorbable everolimus eluting vascular scaffold and XIENCE family…
The COMBO HEALING evaluates the long term healing pattern of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) in routine clinical practice. The primary objective of the study is to the asses the long…
Primary Objective:To evaluate the efficacy and safety of 2 doses of benralizumab in patients with moderate to very severe Chronic Pulmonary Disease (COPD).Secondary Objectives:To evaluate the effect of two doses of benralizumab on:* health status/…
1. To identify and quantify the structural airway wall layers with OCT and rEBUS and correlate this to histology and HRCT2. To identify and quantify the effect of bronchial thermoplasty on the airway wall layers by OCT and rEBUS and correlate this…
The objective of this Phase 3 study is to investigate the safety and efficacy of benralizumab as a treatment for patients with eosinophilic esophagitis.
The objective of this Phase 3 study is to investigate the safety and efficacy of benralizumab as a treatment for patients with eosinophilic gastritis and/or gastro-enteritis.
To compare OCT guided complete revascularization to the predefined objective performance goal (OPG) for all-cause death, stroke, myocardial infarction, or repeated revascularization namely 7% at 12 months. The OPG is derived from the most recent (9-…
To evaluate the efficacy of GSK3511294 100 mg (SC) every 26 weeks versus maintaining existing treatment with either mepolizumabor benralizumab in participants with severe asthma with an eosinophilic phenotype who have previously benefited from anti-…
To evaluate the effect of benralizumab 100 mg on COPD exacerbations in patients with moderate to very severe COPD.
To determine the effect of benralizumab on the rate of asthma exacerbationsSubstudy: - To assess the potential for benralizumab treated patients to reduce their standard of care asthma controller regimen whilemaintaining asthma control.- To assess…
To test the hypothesis: the mode of action of benralizumab being ADCC will target both resident and inflammatory eosinophils whereas mepolizumab only targets inflammatory eosinophils. This will achieved by a head-to-head comparison of the presence…
To test the hypothesis: the mode of action of benralizumab being ADCC will target both resident and inflammatoryeosinophils whereas mepolizumab only targets inflammatory eosinophils. This will achieved by a head-to-headcomparison of the presence of…